Association of p53 Arg72Pro polymorphism with bladder cancer: A meta-analysis

Gene

Volumn 512, Issue 2, 2013, Pages 408-413

  Yang, Zhili ^a   Nie, Shengjie ^d   Zhu, Hui ^b   Wu, Xiaoming ^b   Jia, Shuting ^b   Luo, Ying ^b   Tang, Wenru ^b,c  

^a YUNNAN UNIVERSITY   (China)

^b KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c KUNMING INSTITUTE OF ZOOLOGY   (China)

^d KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; Meta analysis; P53

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ARTICLE; ASIAN; BLADDER CANCER; CAUCASIAN; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MODELS, GENETIC; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84870332109     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.09.085     Document Type: Article

References (41)

1. Bennett W.P., Hussain S.P., Vahakangas K.H., Khan M.A., Shields P.G., Harris C.C. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J. Pathol. 1999, 187:8-18.
2. Bergamaschi D., Samuels Y., Sullivan A., Zvelebil M., Breyssens H., Bisso A., Del Sal G., Syed N., Smith P., Gasco M., Crook T., Lu X. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 2006, 38:1133-1141.
3. Biro E., Kalina I., Salagovic J., Habalova V., Hriv ak M., Valansky L. p53 single nucleotide polymorphisms and bladder cancer. Neoplasma 2000, 47:303-306.
4. Brady C.A., Attardi L.D. p53 at a glance. J. Cell Sci. 2010, 123:2527-2532.
5. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 2009, 9:701-713.
6. Chen W.C., Tsai F.J., Wu J.Y., Wu H.C., Lu H.F., Li C.W. Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol. Res. 2000, 28:293-296.
7. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
8. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003, 33:357-365.
9. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
10. He X.F., Su J., Zhang Y., Huang X., Liu Y., Ding D.P., Wang W., Arparkorn K. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res. Treat 2011, 130:517-529.
11. Horikawa Y., Nadaoka J., Saito M., Kumazawa T., Inoue T., Yuasa T., Tsuchiya N., Nishiyama H., Ogawa O., Habuchi T. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol. Rep. 2008, 20:49-55.
12. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
13. Jiang D.K., Ren W.H., Yao L., Wang W.Z., Peng B., Yu L. Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. Urology 2010, 76:765.e1-765.e7.
14. Jiang D.K., Wang W.Z., Ren W.H., Yao L., Peng B., Yu L. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J. Invest. Dermatol. 2011, 131:220-228.
15. Kuroda Y., Tsukino H., Nakao H., Imai H., Katoh T. p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett. 2003, 189:77-83.
16. Li D.B., Wei X., Jiang L.H., Wang Y., Xu F. Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer. Genet. Mol. Res. 2010, 9:1599-1605.
17. Li Z., Ni M., Li J., Zhang Y., Ouyang Q., Tang C. Decision making of the p53 network: death by integration. J. Theor. Biol. 2010, 271:205-211.
18. Lin H.Y., Huang C.H., Yu T.J., Wu W.J., Yang M.C., Lung F.W. p53 codon 72 polymorphism as a progression index for bladder cancer. Oncol Rep 2012, 27:1193-1199.
19. Mabrouk I., Baccouche S., El-Abed R., Mokdad-Gargouri R., Mosbah A., Said S., Daoud J., Frikha M., Jlidi R., Gargouri A. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann. N. Y. Acad. Sci. 2003, 1010:764-770.
20. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
21. McConkey D.J., Lee S., Choi W., Tran M., Majewski T., Siefker-Radtke A., Dinney C., Czerniak B. Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol. Oncol. 2010, 28:429-440.
22. Murta-Nascimento C., Schmitz-Drager B.J., Zeegers M.P., Steineck G., Kogevinas M., Real F.X., Malats N. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J. Urol. 2007, 25:285-295.
23. Pandith A.A., Shah Z.A., Khan N.P., Rasool R., Afroze D., Yousuf A., Wani S., Siddiqi M. Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. Cancer Genet. Cytogenet. 2010, 203:263-268.
24. Piao J.M., Kim H.N., Song H.R., Kweon S.S., Choi J.S., Yun W.J., Kim Y.C., Oh I.J., Kim K.S., Shin M.H. p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer 2011, 73:264-267.
25. Piao J.M., Kim H.N., Song H.R., Kweon S.S., Choi J.S., Yoon J.Y., Chung I.J., Kim S.H., Shin M.H. p53 codon 72 polymorphism and the risk of esophageal cancer: a Korean case-control study. Dis. Esophagus 2011, 24:596-600.
26. Pim D., Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer 2004, 108:196-199.
27. Pinarbasi E., Percin F.E., Yilmaz M., Akgun E., Cetin M., Cetin A. Association of microsomal epoxide hydrolase gene polymorphism and pre-eclampsia in Turkish women. J. Obstet. Gynaecol. Res. 2007, 33:32-37.
28. Santos L.E., Guilhen A.C., de Andrade R.A., Sumi L.G., Ward L.S. The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer. Urol. Oncol. 2011, 29:291-294.
29. Saran K.K., Gould D., Godec C.J., Verma R.S. Genetics of bladder cancer. J. Mol. Med. (Berl) 1996, 74:441-445.
30. Shi H., Tan S.J., Zhong H., Hu W., Levine A., Xiao C.J., Peng Y., Qi X.B., Shou W.H., Ma R.L., Li Y., Su B., Lu X. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am. J. Hum. Genet. 2009, 84:534-541.
31. Sjalander A., Birgander R., Kivela A., Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum. Hered. 1995, 45:144-149.
32. Song H.R., Kweon S.S., Kim H.N., Piao J.M., Yun W.J., Choi J.S., Hwang J.E., Yoon J.Y., Kim H.R., Park Y.K., Kim S.H., Choi Y.D., Shin M.H. p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer 2011, 14:242-247.
33. Soulitzis N., Sourvinos G., Dokianakis D.N., Spandidos D.A. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 2002, 179:175-183.
34. Srivastava P., Jaiswal P.K., Singh V., Mittal R.D. Role of p53 gene polymorphism and bladder cancer predisposition in northern India. Cancer Biomark. 2010, 8:21-28.
35. Sullivan A., Syed N., Gasco M., Bergamaschi D., Trigiante G., Attard M., Hiller L., Farrell P.J., Smith P., Lu X., Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004, 23:3328-3337.
36. Toruner G.A., Ucar A., Tez M., Cetinkaya M., Ozen H., Ozcelik T. P53 codon 72 polymorphism in bladder cancer-no evidence of association with increased risk or invasiveness. Urol. Res. 2001, 29:393-395.
37. Wu W.J., Kakehi Y., Habuchi T., Kinoshita H., Ogawa O., Terachi T., Huang C.H., Chiang C.P., Yoshida O. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn. J. Cancer Res. 1995, 86:730-736.
38. Ye Y., Yang H., Grossman H.B., Dinney C., Wu X., Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 2008, 112:2467-2474.
39. Ye F., Zhang J., Cheng Q., Shen J., Chen H. p53 Codon 72 polymorphism is associated with occurrence of cervical carcinoma in the Chinese population. Cancer Lett. 2010, 287:117-121.
40. Zhang R., Chen W., Zhang W., Jiang Q., Liu C., Lin Y., Hu Z., Yu S., Xu G. Genetic polymorphisms of p53 codon 72 and bladder cancer susceptibility: a hospital-based case-control study. Genet. Test. Mol. Biomarkers 2011, 15:337-341.
41. Zhou Y., Li N., Zhuang W., Liu G.J., Wu T.X., Yao X., Du L., Wei M.L., Wu X.T. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer 2007, 121:1481-1486.